



COLORECTAL CANCER in Idaho

Colorectal cancer rates are **30% higher** in Idaho communities with higher rates of poverty. Colorectal cancer rates are **60% higher** among American Indian Idahoans than among white Idahoans.

3,632

cases of malignant colorectal cancer were diagnosed among Idahoans during 2017-2021.

1,332

deaths from colorectal cancer among Idahoans during 2018-2022.

3,800+

Idahoans alive on July 1, 2021 had a colorectal cancer diagnosis within the prior 10 years.

Let's beat colorectal cancer!

- **45-75 is the recommend age to receive colorectal cancer screenings.** Healthcare provider recommendation is the primary motivator for Idahoans to get screened.
- **Early detection saves lives!** Colorectal cancer can be prevented or treated if found early.
- **Choose the best screening method – the one that gets done!** Patients have several screening choices, including simple take-home options.

Health Behavior

- **2 in 5 eligible** Idahoans are **NOT** up to date on their colorectal cancer screening (2022 BRFSS).
- **Idaho ranks 42nd** among U.S. states and the District of Columbia for the proportion of adults aged 45-75 who have fully met the USPSTF recommendation for colorectal cancer screening (2022 BRFSS).



7 of every 20 Idahoans diagnosed with colorectal cancer, have died from their cancer within 5 years of diagnosis.

- Rates of colorectal cancers have **decreased 1.3%** per year since 2000.
- In Idaho, males die from colorectal cancer at **1.4 times** the rate of females.
- Hispanic Idahoans have **~10% lower** 5-year survival post-diagnosis than non-Hispanic Idahoans.

This publication has been funded in whole or in part with Federal funds from the National Cancer Institute (NCI) under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention (CDC) under the following Grants or Cooperative Agreements 1 NU58DP006270, NU58DP006314 and DP006084. Its contents are solely the responsibility of the authors and do not necessarily represent the official position of CDC or NCI. March 2024.